Press Release Details

Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer

October 16, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2019-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the appointment of Jan Pinkas, Ph.D., as Senior Vice President, Translational Sciences. The Company also announced that Mike Cooke, Ph.D., Chief Scientific Officer, will leave Magenta to pursue other opportunities.

“We have made tremendous progress at Magenta, with two clinical programs in multiple trials and with our targeted antibody-drug conjugates (ADCs) for patient preparation advancing toward the clinic,” said Jason Gardner, D. Phil., Chief Executive Officer and President, Magenta. “Jan is an expert drug developer who will provide critical translational input and help us accelerate the advancement of our programs as we work to make cures possible for more patients.”

“Magenta is uniquely positioned as the only company taking a comprehensive approach to unlocking the power of stem cell transplant medicine,” said Dr. Pinkas. “I am very excited to be part of the team that is building and expanding upon this foundational and innovative work to bring potentially transformative therapies to patients.”

Dr. Pinkas is a seasoned scientist with deep expertise in leading drug development programs, specifically ADCs. Prior to joining Magenta, he was Head of Translational Research & Development at Immunogen, where he led nonclinical and translational research and development-related activities for all programs in discovery through late-stage clinical development. Dr. Pinkas earned his undergraduate degree in biology from Johns Hopkins University and his doctorate in Molecular and Cellular Biology from the University of Massachusetts at Amherst.

“As Magenta has evolved into a clinical-stage company with a robust pipeline of preclinical assets, Mike has made tremendous contributions. He has built a world-class research organization and advanced our pipeline. Mike and I agreed that now, with a well-established Magenta research platform that is generating strong conditioning ADCs, validated targets, and discovery biology, it is the right time for Mike to explore other opportunities. We wish him well in his new adventure and will always be grateful for his scientific contributions,” added Dr. Gardner.

“I am very proud of Magenta’s rapid progress since our launch three years ago, and I am particularly proud of the cutting-edge scientific work that has come from our platform,” said Dr. Cooke. “I am confident that the scientific groundwork we have laid will help ensure that Magenta achieves its vision to transform the lives of many patients.”

About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Forward-Looking Statement
This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption “Risk Factors” in Magenta’s Registration Statement on Form S-1, as updated by Magenta’s most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Source: Magenta Therapeutics

Manisha Pai, Vice President, Communications & Investor Relations

Privacy Preference Center


The NID and IDE cookies are set by DoubleClick (which is owned by Google) to help build a profile of your interests and show you relevant ads on other sites. The 1P_JAR cookie (from carries out information about how the end user uses the website and any advertising that the end user may have seen before visiting the said website.



Magenta TX uses these cookies to collect information about how visitors use our Site. We use the information to compile reports and to help us improve the Site. The cookies collect information in an anonymous form, including the number of visitors to the Site, where visitors have come to the Site from and the pages they visited. If you do not allow these cookies we will not be able to include your visit in our statistics. You can read the full Google Analytics privacy policy at:

_ga,_gat,_gid, _gali



The OGPC cookie enables the functionality of Google Maps. s_cc Adobe Site Catalyst cookie, determines whether cookies are enabled in the browser. The s_sq and s_vi, Adobe Site Catalyst cookie, stores information about the previous link clicked within the site as well as identify unique visitors, with an ID and timestamp.

OGPC, s_cc, s_sq, s_vi